Sector

Pharma: Is the pandemic investment template about to play out?

The return of the flu season in India and the US, and COVID-19 in China sparked more investor interest in the sector.

Cement demand revives as slack season ends, govt infra spend picks up

Industry margins set to rebound on recovery in prices and drop in fuel costs; UltraTech, JK Cement and Dalmia Bharat are among top analyst stock picks.

UPL: Wait for the right key to open stock re-rating door

The stock's current valuation is at a discount to its long-term historical average and remains inexpensive, compared to its peers

Accenture results signal more trouble for midcap IT stocks

Smaller deals that have powered Indian IT’s order inflows in recent quarters are seeing a slowdown

India data stoke sales optimism for pharma companies

Growth in Indian drug market rebounded in November while flu season is aiding sales in the US

Higher rabi sowing may yield limited gains for agrochemical companies

Lower liquidation of inventories during kharif 2022 can limit sales upside during the winter crop season

Slowdown signs gather pace for IT services companies

Business software companies warn about demand slowdown. With demand for devices weakening, analysts fear IT services spending will be hit next

KIMS: Why we see more upside

KIMS presents a play on the structural demand trend for healthcare facilities in the hinterland

NOCIL: What should investors do amid a muted outlook?

NOCIL is looking through the current soft phase and aiming to address the shortfall in capacities, post FY24

Vijaya Diagnostics: Price stability adds to constructive take

We see Vijaya Diagnostics as a good proxy for regional health-care services consumption play

Gland Pharma’s Europe acquisition fails to excite investors

The company is acquiring the Europe based Cenexi group, whose profit margins and return ratios are much lower than Gland Pharma's

Nifty at record highs – Time to stay put or take the gains?

India is a fundamentally strong long-term growth story. Therefore, every opportunity should be used to buy on decline and not sell on rally

Unified tariffs will aid gas buyers, benefits uncertain for companies

The Petroleum and Natural Gas Regulatory Board plans to implement unified tariff regulations for natural gas infrastructure from April 1, 2023

Why green energy stocks fail to click with investors

Inox Green Energy Services dropped below its IPO price on its listing debut. Others such as ReNew Energy and Sterling and Wilson too have delivered a disappointing performance since listing

For IEX investors, a buyback may provide limited relief

Increased competition in the core electricity trading business is leading analysts to fear it may cede market share to new entrants

Steel sector – Export duty cut a welcome step but with limited benefits

Experts suggest it would not be correct to state that the imposition of export duty was the only key reason for correction in domestic steel prices. It should be noted that prices were already in correction mode when the export duty was imposed.

Aarti Industries: Post demerger, a pure play on aromatic chemistry

The near-term growth profile is blurred by a potential decline in realisations and the persistence of demand weakness

Safari – What after the huge outperformance?

The consistent financial performance and strong sector tailwinds make Safari a very interesting bet for the long term

Dhanuka Agritech: Buyback doesn’t make us a buyer of this stock

Margin pressure remains extended, near-term growth triggers remain limited

What can help Mrs Bectors reduce its valuation gap with Britannia

Mrs Bectors’ revenue increased 37 percent in H1 FY23, faster than the 16 percent rise at Britannia

Q2 results show Indian healthcare sector firmly on recovery path

Healthcare companies expect the growth momentum to continue, driven by the addition of new hospital beds, services and optimisation of existing facilities

Galaxy Surfactants: H2 expected to be weaker than H1FY23

Galaxy Surfactants has improved in the global logistics situation and a drop in raw material prices. In the backdrop of a muted volume growth outlook, we believe investors need to be guarded

PI Industries: Standing strong in testing times

PI’s superior execution with a solid business model accompanied with surplus cash and backward integration strategies makes it a perfect stock to be bought on declines